IMMUNE CHECKPOINT INHIBITORS (ICI)-RELATED DERMATITIS

Clinical trials for IMMUNE CHECKPOINT INHIBITORS (ICI)-RELATED DERMATITIS explained in plain language.

Never miss a new study

Get alerted when new IMMUNE CHECKPOINT INHIBITORS (ICI)-RELATED DERMATITIS trials appear

Sign up with your email to follow new studies for IMMUNE CHECKPOINT INHIBITORS (ICI)-RELATED DERMATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug may tame immunotherapy skin rash and keep cancer treatment on track

Symptom relief Recruiting now

This study tests a JAK inhibitor drug (upadacitinib) for cancer patients who develop a severe skin rash from immunotherapy. The goal is to quickly relieve the rash without using steroids, which can weaken the cancer treatment. About 35 adults with solid tumors and grade 3-4 rash …

Matched conditions: IMMUNE CHECKPOINT INHIBITORS (ICI)-RELATED DERMATITIS

Phase: PHASE2 • Sponsor: Shixiu Wu • Aim: Symptom relief

Last updated May 01, 2026 15:59 UTC

IMMUNE CHECKPOINT INHIBITORS (ICI)-RELATED DERMATITIS

Get alerted when new IMMUNE CHECKPOINT INHIBITORS (ICI)-RELATED DERMATITIS trials appear

New drug may tame immunotherapy skin rash and keep cancer treatment on track